Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) saw a significant increase in short interest during the month of April. As of April 30th, there was short interest totaling 37,392 shares, an increase of 232.8% from the April 15th total of 11,234 shares. Based on an average daily trading volume, of 74,697 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.1% of the company’s stock are short sold.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of NBTX. Royal Bank of Canada increased its holdings in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the period. Optiver Holding B.V. acquired a new stake in Nanobiotix during the third quarter worth about $101,000. Marshall Wace LLP acquired a new stake in Nanobiotix during the fourth quarter worth about $220,000. Finally, Millennium Management LLC acquired a new stake in Nanobiotix during the fourth quarter worth about $390,000. 38.81% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. UBS Group increased their price target on Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Guggenheim increased their price target on Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Finally, TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Nanobiotix currently has an average rating of “Moderate Buy” and a consensus price target of $26.67.
Nanobiotix Stock Down 6.5%
Shares of NBTX stock traded down $3.57 during mid-day trading on Friday, reaching $51.50. The stock had a trading volume of 88,630 shares, compared to its average volume of 98,733. The business’s fifty day moving average is $35.04 and its 200-day moving average is $26.74. Nanobiotix has a 1-year low of $3.64 and a 1-year high of $57.14.
Nanobiotix (NASDAQ:NBTX – Get Free Report) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $3.42 million during the quarter. Equities analysts expect that Nanobiotix will post 0.53 earnings per share for the current year.
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.
Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.
Read More
- Five stocks we like better than Nanobiotix
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
